Daily Low-Dose Subcutaneous Interleukin-2 Added to Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4 + T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)

Mary A. Vogler, Hedy Teppler, Rebecca Gelman, Fred Valentine, Michael M. Lederman, Roger J. Pomerantz, Richard B Pollard, Deborah Weng Cherng, Charles J. Gonzalez, Kathleen E. Squires, Ian Frank, Donna Mildvan, Laura F. Mahon, Barbara Schock

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Daily Low-Dose Subcutaneous Interleukin-2 Added to Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4 + T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)'. Together they form a unique fingerprint.

Medicine & Life Sciences